Moberg Pharma AB (publ)
STO:MOB
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.645
38.92
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MOB stock under the Base Case scenario is 0.61 SEK. Compared to the current market price of 18.26 SEK, Moberg Pharma AB (publ) is Overvalued by 97%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Moberg Pharma AB (publ)
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MOB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Moberg Pharma AB (publ)
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Moberg Pharma AB (publ)
Balance Sheet Decomposition
Moberg Pharma AB (publ)
Current Assets | 347.9m |
Cash & Short-Term Investments | 326m |
Receivables | 16.9m |
Other Current Assets | 5m |
Non-Current Assets | 611.7m |
PP&E | 4.3m |
Intangibles | 574.8m |
Other Non-Current Assets | 32.6m |
Current Liabilities | 27.8m |
Other Current Liabilities | 27.8m |
Non-Current Liabilities | 2.7m |
Long-Term Debt | 2.7m |
Earnings Waterfall
Moberg Pharma AB (publ)
Revenue
|
4.9m
SEK
|
Cost of Revenue
|
-1.7m
SEK
|
Gross Profit
|
3.2m
SEK
|
Operating Expenses
|
-32.1m
SEK
|
Operating Income
|
-28.9m
SEK
|
Other Expenses
|
6.1m
SEK
|
Net Income
|
-22.8m
SEK
|
Free Cash Flow Analysis
Moberg Pharma AB (publ)
SEK | |
Free Cash Flow | SEK |
MOB Profitability Score
Profitability Due Diligence
Moberg Pharma AB (publ)'s profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
Moberg Pharma AB (publ)'s profitability score is 34/100. The higher the profitability score, the more profitable the company is.
MOB Solvency Score
Solvency Due Diligence
Moberg Pharma AB (publ)'s solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
Moberg Pharma AB (publ)'s solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MOB Price Targets Summary
Moberg Pharma AB (publ)
According to Wall Street analysts, the average 1-year price target for MOB is 19.38 SEK with a low forecast of 19.19 SEK and a high forecast of 19.95 SEK.
Dividends
Current shareholder yield for MOB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MOB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one MOB stock under the Base Case scenario is 0.61 SEK.
Compared to the current market price of 18.26 SEK, Moberg Pharma AB (publ) is Overvalued by 97%.